Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B is a research paper published in New England Journal of Medicine (2025). On theSindex it has a DataRank of 0.936. It has been cited 53 times, with 49 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.598
From this paper's citation signal
Citation Network Contribution
0.338
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 49 citers.
NIHR
Grant: (RP-PG-0310-1001)
NIH
Grant: HL094396
EU Horizon 2020
Grant: 945473
Accelerating Research & Development for Advanced Therapies
MRC UK
Grant: G0502121
AN OPEN LABEL DOSE-ESCALATION STUDY OF A SELF COMPLEMENTARY AAV VECTOR FOR GENE THERAPY OF HAEMOPHILIA B
NHLBI NIH HHS
Grant: R01 HL094396
National Institute for Health Research (NIHR)
Grant: RP-PG-0310-1001
FWCI
45.06
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals